23 Feb uniQure
Posted at 19:43h
in
Richard Porter, Chief Business and Scientific Officer
Oct. 5 | 3:15pm | FLW Ballroom F
Amsterdam, Netherlands
(NASDAQ: QURE)
uniQure is delivering on the promise of gene therapy through an innovative adeno-associated virus (AAV)-based technology. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and usher in a new treatment approach for patients living with hemophilia. We’re